Werewolf Therapeutics Q2 2024 net loss $17.2M; positive clinical data for WTX-124 and WTX-330

Werewolf Therapeutics, Inc.

2024-Q2 EPS reported -$0.82

Net loss of $17.2M in Q2 2024 vs $5.1M in Q2 2023; R&D expenses rose to $15.3M from $9.6M.
Cash and equivalents $135.3M at June 30, 2024; sufficient to fund operations through at least Q1 2026.
WTX-124 monotherapy achieved 3 objective responses, including 1 complete response at 18 mg IV Q2W RDE.
WTX-330 showed 1 unconfirmed partial response in melanoma; therapeutically relevant exposure levels achieved.
Updated WTX-124 combination data and expansion arms expected H2 2024; WTX-330 data in Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.